Galectin Therapeutics (GALT) Notes Payables (2024 - 2025)
Galectin Therapeutics' (GALT) quarterly Notes Payables came in at $3.7 million in Q3 2025, up 942.34% year-on-year from $359000.0 in Q3 2024, and up 1126.89% quarter-over-quarter from $305000.0 in Q1 2025.
Galectin Therapeutics (GALT) Notes Payables (2024 - 2025) Analysis & Trends
Galectin Therapeutics' Notes Payables history runs 2 years deep, the most recent figure standing at $3.7 million for Q3 2025.
- On a quarterly basis, Notes Payables rose 942.34% year-over-year to $3.7 million in Q3 2025; TTM through Sep 2025 was $3.7 million, a 942.34% increase from a year earlier, with the FY2024 full-year figure at $369000.0, changed N/A from the prior year.
- Notes Payables climbed to $3.7 million in Q3 2025 per GALT's latest filing, from $305000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $3.7 million in Q3 2025 and bottomed at $305000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 305,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 359,000.00 |